NCT01210820已完成不适用
A Prospective Single Center Study To Evaluate the Feasibility of Intrastromal Arcuate Keratotomy Performed With the IntraLase iFS™ Femtosecond Laser System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- Change in Refractive Astigmatism
研究概览
简要总结
The results of this trial will demonstrate that ISAK performed with the iFS™ femtosecond laser is a safe procedure.
详细描述
Surgeon will perform intrastromal arcuate keratotomy in arc segment patterns using the iFS™ femtosecond laser to treat subjects with refractive astigmatism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, of any race, and at least 21 years of age at the time of the pre-operative examination and signing the consent form
- •Refractive error, no limitation on spherical refractive myopia or hyperopia and refractive astigmatism of 0.75 to 7.00 diopters (D) in the operative eye
- •Best Spectacle Corrected Distance Visual Acuity (BSCVA)
- •Group 1: Natural astigmatism, no cataract: BSCVA of 20/25 or better in both eyes
- •Group 1: Pre cataract surgery, no BSCVA criteria in the operative eye
- •Group 2: Post cataract surgery, BSCVA of 20/25 or better in both eyes
- •Uncorrected Visual Acuity (UCVA) of 20/40 or worse in the operative eye
- •Demonstration of agreement in the operative eye: Corneal astigmatism (as determined by keratometry) must be in agreement with refractive astigmatism (as determined by manifest refractions) as follows: Within ≤ 0.75 D in magnitude and within 15° axis when cylinder ≤ 1.5 D or 10° axis when cylinder > 1.5 D.
- •Preoperative central and peripheral (in planned treatment area) pachymetry of ≥ 500 um in the operative eye
- •Keratometry must be between 38.0 (flat) and 48.0 D (steep) in the operative eye
- •Corneal power (diopters) difference at the 3mm point from topographic center shall be ≤ 1D at the steepest meridian, by topography measurements in the operative eye
- •Intraocular pressure (IOP) of 12 to 21 mm Hg in the operative eye with no glaucomatous retinal changes
- •Stable refractive error in the operative eye, based on an exam (or prescription) at least 6 months prior to the pre-operative examination, and as compared to the pre-operative manifest refraction, must be ≤ 0.75 D (sphere and cylinder) and axis within 15 degrees for eyes with cylinder > 0.5D.
- •Subjects who have worn a contact lens in the operative eye within the past 30 days must remove the soft lens at least 2 weeks prior and a rigid or toric lens at least 3 weeks prior to baseline measurements. In addition, rigid or toric lens wearers must demonstrate stability in topography, keratometry and refraction before proceeding with surgery. Refractive stability is defined as a change of not more than 0.50 D in manifest sphere, cylinder, or keratometry (either axis) as compared to the unadjusted preoperative refraction in two visits at least one week apart.
- •Willing and capable of returning for follow-up examinations for the duration of the study
- •Subject must sign and be given a copy of the written Informed Consent Form
排除标准
- •Abnormal topography, including evidence of keratoconus or pellucid marginal degeneration, in either eye
- •Irregular astigmatism in the operative eye
- •Evidence of clinically significant corneal opacity/scar in the operative eye within an 8 mm diameter zone of the visual axis
- •Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study, as determined by verbal inquiry
- •Concurrent use of topical or systemic medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment
- •History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis
- •History of active ophthalmic disease or other non-refractive abnormality (including, but not limited to, corneal dystrophy, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), retinal detachment/repair, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma NOTE: Subjects with open angle glaucoma, regardless of medication regimen or control, or an IOP greater than 21 mm Hg at baseline, are specifically excluded from eligibility.
- •Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course
- •Participation in any other conflicting ophthalmic drug or device clinical study during the period of participation in this clinical investigation -
结局指标
主要结局
Change in Refractive Astigmatism
时间窗: 6 months
Change in mean cylinder (assessed by manifest refraction) compared to baseline.
Change in Keratometric Cylinder
时间窗: 6 Months
Change in mean keratometric cylinder (as measured by keratometry) compared to baseline.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Cataract Surgery: Femto LDV Z8 Versus ConventionalCataractNCT02351271Ziemer Ophthalmic Systems AG130
已完成
2 期
Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser SystemCorneal AstigmatismNCT01348854Abbott Medical Optics40
已完成
不适用
WaveLight® Refractive Flap Accuracy StudyRefractive ErrorNCT01941485Alcon Research60
已完成
不适用
A Real-World Registry to Investigate the Performance of LenSx® Laser in Chinese PatientsCataractsNCT02396719Alcon Research1,541
已完成
不适用
Femtosecond Laser-assisted Anterior Lamellar KeratoplastyCorneal OpacityKeratoconusNCT02301598The S.N. Fyodorov Eye Microsurgery State Institution13